Table 3 Comparison of adverse events during the first 14 days after treatment between the two treatments
Adverse events | UK-12 h(n = 70) | UK-2 h(n = 59) | P |
|---|---|---|---|
Death | 1(1.4) | 2(3.4) | |
Due to PE | 1(1.4) | 1(1.7) | 0.462 |
Due to Bleeding | 0(0) | 0(0) | |
Due to Other Comordities | 0(0) | 1(1.7) | |
Recurrent PE | 1(1.4) | 0(0) | 0.858 |
Fatal | 1(1.4) | 0(0) | |
Non fatal | 0(0) | 0(0) | |
Bleeding complications | 10(14.3) | 8(13.6) | 0.332 |
Major bleeding | 4(5.7) | 6(10.2) | |
Fatal bleeding | 0(0) | 0(0) | |
Others | 4(5.7) | 6(10.2) | |
Minor Bleeding | 6(8.6) | 2(3.4) |